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ABSTRACT 
Background: Matrix metalloproteinases (MMPs), MMP-inhibitors (TIMPs), 
ADAM(TS)s and growth factors are involved in inflammation and tissue damage and 
repair, all occurring in inflammatory bowel disease (IBD). We studied the impact of 
anti-inflammatory therapy with infliximab on mucosal expression of these tissue 
remodeling genes in IBD patients. 
Methods: Mucosal gene expression of 23 MMPs, 4 TIMPs, 50 ADAM(TS)s and 158 
growth factors was investigated in 61 IBD patients before and after first infliximab 
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therapy and in 12 controls, with microarrays and quantitative RT-PCR. Protein 
localization, mucosal gelatinase levels and net gelatinolytic activity were investigated 
by immunohistochemistry, zymography analysis and gelatin degradation assay, 
respectively. 
Results: In active IBD patients before infliximab vs. controls, gene expression of 
many MMPs, TIMPs, ADAM(TS)s and growth factors was upregulated, whereas 
colonic expression of MMP28 and TGFA, and ileal expression of ADAMDEC1 and 
AGT were downregulated. After controlling inflammation with infliximab, most gene 
dysregulations observed at baseline were restored in responders. Increased ratio of 
MMP1/TIMP1 expression at baseline in active IBD was restored in responders with 
colonic mucosal healing. Immunohistochemistry for MMP1, MMP3, TIMP1 and 
REG1A showed higher protein levels in active IBD patients vs. inactive patients or 
controls. With zymography analysis and gelatin degradation assay higher gelatinase 
levels and net gelatinolytic activity were measured before infliximab and levels 
normalized after infliximab. 
Conclusions: Our data suggest that suppression of inflammation results in arrest of 
epithelial damage and subsequent mucosal healing. Therefore, the therapeutic 
potential of agents targeting MMPs or growth factors as primary therapy seems 
rather complex.  
 
Key Words: inflammatory bowel disease, infliximab, mucosal expression, tissue 
remodeling genes  
 
INTRODUCTION 
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Crohn’s disease (CD) and ulcerative colitis (UC) are chronic disabling inflammatory 
bowel diseases (IBD) with increasing prevalence throughout the whole world. IBD 
occurs mostly in young people and often leads to a greatly decreased quality of life, 
with (bloody) diarrhea and abdominal pain as major gastrointestinal symptoms. 
Despite extensive efforts, the exact pathogenesis of IBD remains unknown. However, 
it is believed that the chronic intestinal inflammation in IBD is the result of an 
inappropriate and ongoing activation of the mucosal immune system towards the 
(normal) luminal microbiota in genetically susceptible individuals. This activation of 
the mucosal immune system is most likely facilitated by defects in both the intestinal 
epithelial barrier function (“leaky mucosal barrier”) and the mucosal immune system 
(“loss of immune tolerance”) (1).  
Chronic intestinal inflammation leads to tissue damage and subsequent tissue repair, 
and all these events are accompanied by an increased turnover of the extracellular 
matrix (ECM). Disturbance in the balance between the synthesis and breakdown of 
ECM components is involved in the pathological findings of IBD, leading to 
progressive tissue destruction (e.g. ulcers and fistulas) or excessive deposition of 
collagens (major component of ECM) resulting in fibrosis (2). Matrix 
metalloproteinases (MMPs) and their inhibitors and gro th factors are important 
players in this tissue remodeling process. MMPs are a family with over 20 members 
of Zn2+-dependent endopeptidases that degrade most components of the ECM in 
inflammatory diseases. Their proteolytic activity is tightly controlled by endogenous 
inhibitors, including the tissue inhibitors of metalloproteinases (TIMPs) (3). Previous 
selective studies in IBD have shown that the balance between specific MMPs and 
TIMPs and their expression are dysregulated in IBD (4-6), but a general picture 
remains so far elusive. The MMPs share sequential and structural motifs with ADAMs 
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(a disintegrin and metalloproteinase) and ADAMTSs (ADAMs with thrombospondin 
type 1 motif), which have both adhesive and proteolytic activities. Growth factors are 
involved in the modulation of intestinal inflammation and repair during IBD, having a 
critical role in cellular proliferation, differentiation and angiogenesis (7). They also 
promote wound healing by stimulating ECM synthesis, in part by modulating the 
balance between MMPs and TIMPs (8). Finally, an intrinsic network of interactions 
between inflammatory cytokines and growth factors with the balances of proteinases 
and inhibitors exists in acute and chronic inflammatory diseases, in which tumor 
necrosis factor (TNF) is a key regulator (9). These interactions not only include the 
induction of growth factors and proteases by upstream agonists, such as TNF, but 
also the activation, potentiation and degradation of growth factors and proteinases by 
extracellular proteases (3;10). Infliximab (Remicade; Centocor, Inc., Malvern, PA, 
USA), a chimeric monoclonal antibody to tumor necrosis factor-alpha (TNF-α), has 
become the mainstay of therapy in refractory IBD (11). Infliximab dramatically 
improves the quality of life in IBD patients. Besides inducing and maintaining 
remission in refractory IBD patients, treatment with infliximab leads to new treatment 
goals such as intestinal mucosal healing and a reduction in hospitalizations and 
surgeries on the long-term. The intestinal mucosa of IBD patients is composed of 
different and changing cell types. The interactions between the immune cell 
populations and the non-immune cell types, including epithelial, mesenchymal, and 
microvascular endothelial cells, are important in the pathogenesis of IBD. Gene 
expression microarray profiling of the intestinal mucosa will represent an average of 
these different cell types, and gene expression by some cell populations (e.g. 
epithelial cells) may be decreased to the total mRNA pool, reflecting mucosal 
trafficking of inflammatory cell types in IBD(12).  
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The study of gene expression in patients with IBD who achieved mucosal healing 
under infliximab in comparison with the gene expression before treatment allows us 
to obtain insights into the importance of the different mediators of inflammation, 
tissue degradation and tissue repair. Therefore, we investigated the intestinal 
mucosal gene expression of MMPs, TIMPs, ADAM(TS)s and growth factors in 
patients with active IBD, as well as the impact of anti-inflammatory therapy with 
infliximab on the mucosal expression of these genes, with the use of gene expression 
microarray technology. Validation of specific microarray data for selected genes was 
performed by quantitative real-time reverse-transcription PCR (qRT-PCR). In 
addition, immunohistochemistry was performed to evaluate protein levels and 
localization of MMP1, MMP3, TIMP1 and REG1A in active, inactive and control 
colonic and ileal mucosa. Zymography analysis was performed to investigate 
gelatinase levels before and after treatment with infliximab. Finally, a gelatin 
degradation assay was used to evaluate net gelatinolytic activity in the mucosal 
biopsies. 
 
MATERIALS and METHODS 
MMPs, TIMPs, ADAM(TS)s and growth factors 
The gene expression of 23 MMPs, 4 TIMPs and 50 ADAM(TS)s and the expression 
of 158 genes encoding peptides/proteins with growth factor activity (see 
Supplementary table 1 for a detailed list of the genes) were investigated in intestinal 
mucosal biopsies obtained from normal controls and from IBD patients before and 
after their first infliximab treatment, using gene expression microarray technology.  
 
Patients and biopsy specimens  
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This was a prospective observational cohort study (ClinicalTrials.gov number, 
NCT00639821). Sixty-one patients with active IBD, including 24 UC, 19 Crohn’s 
colitis (CDc) and 18 Crohn’s ileitis (CDi), refractory to corticosteroids and/or 
immunosuppression were studied. In table 1 the baseline characteristics of the 
patients and controls are shown.  
A control group with normal mucosa of 12 individuals [6 colon and 6 ileum] who 
underwent endoscopy for screening for polyps was also included. The patients 
underwent endoscopy with biopsies from diseased bowel (colon for UC and CDc and 
ileum for CDi) within a week prior to the first intravenous infliximab infusion of 5 
mg/kg body weight. The patients underwent a second endoscopy with biopsies 4 
weeks after the first infliximab infusion in case of a single infusion and at 6 weeks if 
they received a loading dose of infliximab at weeks 0, 2 and 6. The biopsies were 
taken at sites of active inflammation but at a distance of ulcerations. In the case of 
healing at control endoscopy, the biopsies were obtained in the areas where lesions 
were present before therapy. The endoscopist was not blinded to treatment. Half of 
the biopsies were immediately snap-frozen in liquid nitrogen and stored at -80°C until 
RNA isolation, except for the biopsies from 1 CDc patient after infliximab treatment 
because of poor technical quality. The rest of the biopsies were fixed in Carnoy’s 
fixative for up to 5 hours and then dehydrated, cleared and paraffin-embedded. 
Haematoxylin-eosin stained slides from the paraffin blocks of each patient were used 
to score the chronic intestinal inflammation, using a previously reported histological 
scoring system for UC (12) and for CD (13). 
The response to infliximab therapy was assessed at the time of the second 
endoscopy, based on endoscopic and histologic findings. In the colon, the response 
was defined as a complete endoscopic mucosal healing (absence of ulcers) with a 
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decrease of at least 3 points on the histological score for CDc (13) and as a decrease 
to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the 
histological score for UC (12;14). Patients who did not achieve this healing were 
considered non-responders although some of them showed endoscopic and/or 
histologic improvement. Of the 43 IBDc patients, we scored 20 responders (8 UC and 
12 CDc) and 23 non-responders (16 UC and 7 CDc). When the same response 
criteria of CDc were used for CDi, there was only one patient who showed in the 
ileum a complete endoscopic and histologic healing. Therefore, we used response 
criteria with lower stringency than complete healing in CDi. Patients with a clear 
improvement of the ulcerations and a decrease on the histological score (13) were 
defined as responders. Of the 18 CDi patients, 8 were (partial) responders and 10 
were non-responders.  
The characteristics of age, sex and smoking were compared between patients and 
controls. These comparisons were performed with the Mann-Whitney U-test for 
continuous variables and Fisher’s exact test for categorical variables, using SPSS 
software (Chicago, IL) (Table 1). A p-value ≤ 0.01 was considered significant.  
 
Whole-genome gene expression analysis 
As previously described (15), total RNA was extracted from the biopsy specimens 
and used to analyze the gene expression via Affymetrix Human Genome U133 Plus 
2.0 Arrays (Affymetrix, Santa Clara, CA, USA), which are comprised of 54 675 probe 
sets covering the whole genome. The microarray data have been submitted in 
MIAME (Minimum Information About a Microarray Experiment) format to the Gene 
Expression Omnibus database (series accession number GSE16879).  
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Bioconductor tools (16) in R (version 2.7.2, http://www.r-project.org/) were used to 
analyze the Affymetrix raw data (.cel files). The robust multichip average method was 
performed on the Affymetrix raw data to obtain a log2 expression value for each 
probe set (17). Probe set annotations were obtained through the Affymetrix NetAffx 
website (http://www.affymetrix.com/analysis/index.affx) or the UCSC Genome 
Browser website (http://genome.ucsc.edu/) or the NCBI website 
(http://www.ncbi.nlm.nih.gov/). For comparative analysis, linear models for microarray 
data (LIMMA) (18) were performed for all probe sets present on the microarray to 
identify probe sets that are different between the groups, based on moderated t-
statistics. For multiple testing correction, the false discovery rate (FDR) was 
estimated from p-values derived from the moderated t-statistics using the method of 
Benjamini and Hochberg (19).  
 
qRT-PCR analysis 
To confirm the microarray data, qRT-PCR was performed for MMP1, MMP28, TIMP1, 
ADAM9, TFF1, TGFB1 and β-actin (as endogenous reference gene). cDNA was 
synthesized from 0.5 µg of total RNA from the same samples as for microarray 
analysis, using the RevertAid H Minus First Strand cDNA synthesis kit (Fermentas, 
St. Leon-Rot, Germany), following the manufacturer’s protocol. Primers and dual-
labelled probes were designed with OligoAnalyzer software 
(http://eu.idtdna.com/analyzer/applications/oligoanalyzer/default.aspx) and 
synthesized by Sigma-Aldrich (Bornem, Belgium) (Supplementary table 2). 
Multiplex real-time PCR was performed in a final reaction volume of 25 µl on a Rotor-
Gene 3000 instrument (Corbett Research, Mortlake, Australia), using QuantiTect 
Multiplex PCR NoROX Kit (Qiagen, Venlo, NL), according to the manufacturer’s 
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instructions. Cycle threshold values were determined by Rotor-Gene 6.0.16 software. 
All samples were amplified in duplicate reactions. The relative expression of target 
mRNA levels were calculated as a ratio relative to β-actin reference mRNA (20). The 
results were analyzed with SPSS software, using Mann-Whitney U-test for unpaired 
samples and Wilcoxon signed-rank test for paired samples. A p-value ≤ 0.01 was 
considered significant. 
 
Protein expression by immunohistochemistry 
To localize MMP1, MMP3, TIMP1 and REG1A in the intestinal mucosa, 
immunohistochemistry was performed on 5 µm-thick sections that were cut from 
paraffin blocks of formalin-fixed endoscopic biopsies from IBD patients and control 
individuals. After drying, deparaffinization and rehydration, epitope retrieval was 
performed at low pH for MMP1 and TIMP1, and at high pH for MMP3 and REG1A 
(Dako PT Link machine, Dako Belgium NV, Heverlee, Belgium). Sections were then 
washed 3 times 5 min (Envision Flex wash buffer, Dako) and Envision Flex 
Peroxidase-Blocking Reagent (Dako) was applied for 10 min at room temperature. 
After a second wash step, sections were incubated with an anti-human MMP1 rabbit 
polyclonal antibody (Bio-Rad AbD Serotec GmbH, Düsseldorf, Germany; dilution 
1/100), or with an anti-human MMP3 rabbit polyclonal antibody (Sigma-Aldrich, 
dilution 1/200), or with anti-human TIMP1 mouse monoclonal antibody (clone 102D1; 
Millipore, Overijse, Belgium; dilution 1/75), or with anti-human REG1A rabbit 
polyclonal antibody (Sigma-Aldrich, dilution 1/300) for 30 min at room temperature. 
Following a third wash step, bound primary antibody was visualized by incubating the 
slides for 30 min with Envision Flex/HRP (Dako) and application of the Envision 
DAB+ Chromogen (Dako) for 10 min at room temperature. After rinsing, the slides 
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were counterstained with haematoxylin, dehydrated, cleared and mounted. All the 
stains were evaluated by an experienced pathologist (GDH). Aside previous uses of 
the indicated antibodies, immunohistochemistry controls included omission of primary 
antibody and always yielded the expected negative signals. 
 
Zymography analysis 
Snap-frozen mucosal biopsies from a subset of active CDi patients (n=3) and IBDc 
patients (n=3) before and after treatment with infliximab, as well as control samples 
(3 ileum, 2 colon) were investigated with gelatin zymography analysis as described 
previously (21). Briefly, the weight of the biopsies was determined and 500 µl of lysis 
buffer was added (50 mM Tris, 0.5 M NaCl, 10 mM CaCl2, 0.5% Triton-X 100, 
complete EDTA-free protease inhibitors (1 tablet/10 ml (Hoffmann-La Roche, Basel, 
Switzerland) (pH 7.5)). The tissue was then homogenized with the Precellys 24 
system (Bertin Technologies, Montigny-le-Bretonneux, France) and centrifuged 15 
min at 20800 g at 4°C. The supernatants, of which the volume was normalized to the 
starting weight of the biopsies, was then pre-purified using gelatin-Sepharose beads 
(GE healthcare, Buckinghamshire, United Kingdom) and mini-spin columns (Bio-Rad 
Laboratories, Hercules, CA, USA) (22). The bound gelatinases were eluted from the 
column with 20 µl Tris/glycine/SDS non-reducing loading buffer (Invitrogen, Carlsbad, 
CA, USA) and the pre-purified samples were then separated in 7.5% acrylamide gels 
copolymerized with 1mg/ml porcine gelatin (Sigma-Aldrich, St. Louis, MO, USA). The 
gels were then washed with 2.5% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) 
for 40 min and incubated overnight at 37°C in 50 mM Tris-HCl (pH 7.5) 
supplemented with 10 mM CaCl2 (Sigma-Aldrich, St. Louis, MO, USA). The gels were 
stained with 0.25% Coomassie Brilliant Blue-R (Sigma-Aldrich, St. Louis, MO, USA) 
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and scanned using standard settings. Band densities were analyzed with Image J 
1.48 software (NIH Windows version) and the obtained densities of different 
gelatinase forms were plotted as a ratio versus proMMP2 levels. 
 
Gelatin degradation assay 
The gelatin degradation assay was performed on snap-frozen mucosal biopsies from 
a subset of active CDi patients (n=3) and IBDc patients (n=3) before and after 
treatment with infliximab, as well as control samples (3 ileum, 3 colon). First, proteins 
were extracted from the biopsy samples in 500 µl assay buffer (150 mM NaCl, 50 
mM Tris, 5 mM CaCl2, 0.05% Tween20). Next, the net gelatinolytic activity was 
measured with the use of a previously described gelatin degradation assay (23). 
Briefly, the samples were added (duplicates) to a 96-well plate (chimney, black, clear 
bottom, Greiner Bio-one, Frickenhausen, Germany) and DQTM-gelatin (Invitrogen, 
Carlsbad, CA, USA) was added to a final concentration of 2.5 µg/ml. Immediately 
thereafter, the plate was placed in a fluorescence reader (FL600 Microplate 
fluorescence reader, Biotek, Highland Park, IL, USA) and fluorescence was 
measured every 10 min for 4h at 37°C.  
 
ETHICAL CONSIDERATIONS 
The study was carried out at the University Hospital Gasthuisberg in Leuven 
(ClinicalTrials.gov number, NCT00639821). Written informed consent was obtained 
from all individuals and the study was approved by the University Hospital Ethics 
Committee.  
 
RESULTS 
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Gene expression of tissue remodeling genes in IBD intestinal mucosa before 
and after first infliximab therapy 
The intestinal mucosal gene expression microarray profiles were compared between 
normal controls, patients pre- and post-infliximab therapy in UC, CDc, IBD colitis 
(IBDc; UC and CDc together) and CDi. 
In the current microarray study, we studied the intestinal mucosal gene expression of 
23 MMPs, 4 TIMPs, 50 ADAM(TS)s and 158 growth factors. On the Affymetrix 
Human Genome U133 Plus 2.0 Array, the 23 MMPs were represented by 45 probe 
sets, the 4 TIMPs by 9 probe sets, the 50 ADAM(TS)s by 112 probe sets and the 
growth factors by 318 probe sets (Supplementary table 1). We only focussed on 
those probe sets that were expressed in the gut. Therefore, the probe sets with low 
overall intensity were excluded and only the probe sets with an intensity more than 
log2(50) in at least 10% of the samples (n=133) were included. This filter criterion 
leaves 22 probe sets representing 13 MMPs, 8 probe sets representing 3 TIMPs, 18 
probe sets representing 14 ADAM(TS)s and 100 probe sets representing 69 growth 
factors for further analysis (Supplementary table 1). The results for these filtered 
probe sets were selected from all performed comparative analyses (Supplementary 
table 3). In the comparative analyses, the filtered probe sets with > 2-fold change 
and FDR < 0.05 were considered biologically significant. Additionally, we found that 
the characteristic age was significantly different between IBD patients and controls 
(Table 1). To investigate if age has an impact on the expression of the tissue 
remodeling genes in IBD and controls, LIMMA analysis between IBD patients (before 
therapy) and controls was performed with age as confounding factor. The results of 
the comparative analysis with age as confounder were similar as for the analysis 
without age as confounding factor. So there was no impact of the age on the 
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expression of the tissue remodeling genes between IBD patients and controls 
(Supplementary table 4). Moreover, no evidence was found for age-related 
differential gene expression in active IBD patients and controls (results not shown). 
 
Expression of MMPs, TIMPs and ADAM(TS)s  
First, we studied whether differences existed in gene expression of MMPs, TIMPs 
and ADAM(TS)s in active UC as compared with active CDc. We observed no 
significant gene expression differences at baseline (= pre-infliximab therapy) in 
inflamed colon between UC and CDc (Supplementary table 3). Second, we 
investigated the differential expression in MMP, TIMP and ADAM(TS) genes at 
baseline between active CDc and active CDi. Only MMP12 expression was more 
than 2-fold significantly downregulated at baseline in active CDi as compared to 
active CDc (Supplementary table 3).  
Third, we investigated the differential gene expression of MMPs, TIMPs and 
ADAM(TS)s in inflamed mucosa of IBD patients and the effect of infliximab therapy 
on the expression of these genes (Table 2 and 3). In IBDc, the gene expression 
levels of MMP1-3, MMP7, MMP9-10, MMP12, MMP19, TIMP1-2, ADAM9, ADAM19, 
ADAM28, ADAMTS1 and ADAMTS9 were more than 2-fold significantly increased, 
whereas only MMP28 gene expression was more than 2-fold significantly decreased 
at baseline in inflamed colon as compared to control colons. Most of the MMP and 
TIMP genes upregulated at baseline in active IBDc decreased more than 2-fold 
significantly after infliximab therapy in IBDc responders when compared to baseline, 
and MMP28 expression was more than 2-fold significantly increased (Table 2). In 
contrast, no significant changes of these genes were observed in IBDc non-
responders after therapy when compared to their baseline samples (Supplementary 
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table 3). These findings validate reciprocally the microarray data versus the 
endoscopic/histological findings. None of the MMP, TIMP and ADAM(TS) genes 
remained dysregulated after infliximab therapy in IBDc responders as compared to 
control colons, whereas most of the dysregulated genes at baseline remained 
dysregulated after therapy in IBDc non-responders when compared to control colons 
(Table 2).  
Furthermore, we observed that in active IBDc before therapy versus control colons 
the fold change of the significant MMP1 (85.57x), MMP3 (67.93x), MMP10 (16.98x) 
and MMP12 (28.72x) was much higher than the fold change of the significant TIMPs 
[TIMP1 (11.51x) and TIMP2 (2.16x) (Table 2). In IBDc responders after therapy 
versus control colons, the fold change for both MMPs and TIMPs was around 1 
(Table 2).  
In CDi, the gene expression levels of MMP1, MMP3, MMP7, MMP10 and TIMP1 
were more than 2-fold significantly upregulated, whereas only ADAMDEC1 gene 
expression was more than 2-fold significantly downregulated at baseline in inflamed 
ileum as compared to control ileums. After infliximab therapy, no genes remained 
dysregulated in CDi responders as compared to control ileums, whereas the 
expression levels of MMP1, MMP3 and TIMP1 remained more than 2-fold 
significantly upregulated in CDi non-responders when compared to control ileums 
(Table 3).  
Moreover, the ratio between the fold change of MMP1 and TIMP1, MMP3 and 
TIMP1, and MMP10 and TIMP1 in active CDi before therapy vs. control ileums was 
also increased (Table 3) as in IBDc before therapy. 
Next, we studied the correlation of the expression of the MMP, TIMP and ADAM(TS) 
genes that were dysregulated at baseline in active disease with the gene expression 
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of granulocyte markers (S100A8, S100A9 and S100A12), an inflammatory marker 
(interleukin 8 (IL8)) and an epithelial marker (villin 1 (VIL1)). The correlations were 
analyzed with the Spearman’s Rank Correlation test using the microarray log2 mRNA 
expression values, and a p-value ≤ 0.01 was considered significant (Supplementary 
table 5). The colon (n=91) and ileum (n=42) samples were analysed separately. A 
highly positive significant correlation was found for the mRNA levels for all 
upregulated MMPs, TIMPs and ADAM(TS)s with the mRNA levels of S100A8, 
S100A9, S100A12 and IL8 for both colon and ileum samples. A negative significant 
correlation was seen between the colonic mRNA levels of the downregulated MMP28 
and VIL1, and between the ileal mRNA levels of the downregulated ADAMDEC1 and 
VIL1. 
 
Expression of growth factor genes 
Two rationales incited us to study growth factor gene expression levels in intestinal 
biopsies. First, many balances between MMPs and inhibitors are regulated by growth 
factors, and ADAM(TS)s have a prominent role in growth and development. Second, 
IBD results in epithelial tissue regenerative processes and healing processes involve 
growth regulating cytokines. 
First, we studied the differential gene expression of growth factors at baseline in 
inflamed colon between active UC and active CDc, and we found no significant 
differences in gene expression of growth factors at baseline between active UC and 
active CDc (Supplementary table 3). Second, the differential gene expression of 
growth factors was studied at baseline between active CDc and active CDi. At 
baseline, the gene expression levels of FGF9, MACC1, MST1 and PDGFC were 
more than 2-fold significantly higher, and AREG, BMP2, CTGF and LEFTY1 gene 
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expression levels were more than 2-fold significantly lower in active CDi when 
compared to active CDc (Table 4). 
Third, the gene expression of growth factors was studied in inflamed mucosa of 
active IBD patients and the impact of infliximab therapy on the expression of these 
genes was evaluated (Tables 5 and 6). In IBDc, the colonic gene expression of AGT, 
ANGPTL2, AREG, CECR1, CTGF, FGF7/KGFLP1/KGFLP2, GMFG, HBEGF, 
HDGFRP3, INHBA, JAG1, MANF, REG1A, TFF1-2, TGFB1 and TYMP was more 
than 2-fold significantly upregulated, whereas only TGFA gene expression was more 
than 2-fold significantly downregulated before infliximab therapy in inflamed colon as 
compared to control colons. The expression of many growth factor genes which were 
upregulated at baseline in inflamed IBD colon were no longer significantly 
upregulated after therapy in IBDc responders when compared to control colons. As 
an exception, we observed that the colonic expression levels of AREG and JAG1 
remained more than 2-fold significantly higher in IBDc responders after infliximab 
therapy as compared to control levels in the colon (Table 5). In contrast, most of the 
growth factor dysregulations observed at baseline in inflamed IBDc colon remained 
dysregulated after infliximab therapy in IBDc non-responders (Table 5). Of notice, the 
gene expression level of REG1A was more than 70 times higher in IBDc when 
compared to control colons and after infliximab treatment the expression was 
restored in IBDc responders but not in IBDc non-responders. 
In CDi, only TFF1 mRNA expression was more than 2-fold significantly increased at 
baseline in inflamed ileum when compared to control ileums. In contrast with inflamed 
CDc colon, AGT mRNA expression levels were more than 2-fold significantly 
decreased at baseline in inflamed CDi ileum versus control ileums. After infliximab 
therapy, only AGT expression remained downregulated in CDi responders, and TFF1 
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and AGT expression remained significantly dysregulated in CDi non-responders as 
compared to control ileums (Table 6).  
Finally, all upregulated growth factor genes at baseline in active IBD correlated 
positively with the granulocyte markers (S100A12, S100A8 and S100A9) and the 
inflammatory marker IL8, except for the colonic mRNA levels of AREG, HBEGF, 
JAG1 and the ileal AGT mRNA levels. A strong positive significant correlation was 
found between the colonic mRNA levels of the downregulated TGFA and the 
epithelial marker VIL1, and no correlation was seen between the ileal mRNA levels of 
the downregulated AGT and VIL1  (Supplementary table 5). 
 
Validation of selected microarray data by qRT-PCR 
We were able to confirm with the use of qRT-PCR the gene expression microarray 
results for MMP1, MMP28, TIMP1, ADAM9, TFF1, TGFB1, the ratio MMP1/TIMP1 
(Figures 1 and 2, and Supplementary table 6) between controls and IBD patients 
before and after treatment.  
As compared to control colons, the gene expression levels of MMP1, TIMP1, ADAM9 
and TGFB1 were all significantly increased, and only MMP28 was significantly 
decreased in the inflamed colon of active IBDc patients. None of these genes 
remained significantly dysregulated after therapy in IBDc responders vs. control 
colons, whereas in IBDc non-responders the gene expression of  MMP1, TIMP1, 
ADAM9 and MMP28 remained significantly dysregulated after therapy when 
compared to control colons. Moreover, the ratio of MMP1/TIMP1 gene expression 
was significantly increased in active IBDc versus control colons, and this imbalance 
was restored after therapy in IBDc responders when compared to control colons.   
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As compared to control ileums, the gene expression levels of MMP1, TIMP1, 
ADAM9, TFF1 and the ratio MMP1/TIMP1 were all significantly increased in the 
inflamed ileum of CDi patients. After infliximab therapy, none of these genes 
remained significantly dysregulated in CDi responders vs. control ileums, except for 
MMP1 gene expression which remained significantly upregulated after therapy in CDi 
responders vs. control ileums. This increased MMP1 gene expression after therapy in 
CDi responders (7.21 times increase) was also observed by microarray analysis but 
no significance was reached (FDR=0.13) (Table 3 and Supplementary table 3).   
 
Protein expression of MMP1, MMP3, REG1A and TIMP1 in ileal and colonic 
biopsies 
Immunohistochemistry was performed to localize MMP1, MMP3, REG1A and TIMP1 
in the intestinal mucosa of controls and IBD patients with active and inactive disease. 
In normal mucosa MMP1 was expressed in the cytoplasm of primitive cells at the 
base of the crypts (Figure 3A), whereas active IBD mucosa showed an increased 
expression of MMP1 in immature and surface epithelium cells according to the 
regeneration of the epithelial layer (Figure 3A). Moreover, MMP1 expression was 
found in endothelial cells of active IBD patients nearby active inflammation areas. In 
normal mucosa, MMP3 was detected in mononuclear inflammatory cells (Figure 3B). 
In active IBD mucosa, there was an increased expression of MMP3 according to the 
increased amount of mononuclear inflammatory cells (Figure 3B). REG1A was 
expressed mainly in the Paneth cells at the base of the crypts in normal mucosa 
(Figure 3C), whereas an enhanced expression of REG1A was seen in immature and 
surface epithelium cells of active IBD patients (Figure 3C). TIMP1 expression was 
seen in enteroendocrine cells at the base of the crypts, but no clear differences could 
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be found in TIMP1 expression levels between control, inactive or active mucosa 
(Figure 3D). 
 
Gelatinase levels and net gelatinolytic activities before and after treatment with 
infliximab 
Zymography analysis was performed to determine gelatinase (MMP9 and MMP2) 
levels in mucosal biopsies taken from 3 IBDc and 3 CDi responder patients before 
and after infliximab, and 5 controls (3 ileum, 2 colon). In figure 4 and 
supplementary figure 1, a clear trend for higher gelatinase levels was seen before 
infliximab therapy when compared to levels after therapy or control levels. 
Interestingly, no NGAL-MMP9 or activated MMP9 levels were measured in control 
tissues. In addition, a gelatin degradation assay was performed to determine the net 
gelatinolytic activity present in the mucosal biopsies. Overall, a trend was seen for 
elevated gelatinolytic activity levels before infliximab treatment and a decrease to 
control activity levels after treatment (Figure 5). Moreover, two patients (1 CDi and 1 
IBDc responder) had markedly high activity levels before infliximab.  
 
DISCUSSION 
In IBD a disturbed and high intestinal turnover is observed during the sequence of 
inflammation, tissue destruction and repair, resulting in tissue morphological changes 
(e.g. ulcers, fibrosis) (2;4;7;24;25). MMPs, ADAM(TS)s, TIMPs and growth factors 
play a major role in this tissue remodeling process. Achievement of mucosal healing 
in IBD responders to infliximab treatment allowed us to identify, during the evolution 
of the healing process, the changes that occur with healing in mediators of mucosal 
damage and repair in IBD.  
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In the present gene expression microarray study we investigated the intestinal 
mucosal expression of MMP, ADAM(TS), TIMP and growth factor genes in active IBD 
and the influence of thorough downregulation of inflammation by infliximab therapy 
on the mucosal expression of these genes. With the use of qRT-PCR we confirmed 
the microarray data of selected genes.  
In this study, no significant differences in expression of these genes were found at 
baseline in inflamed colon between CDc and UC, whereas there was a large 
difference in gene expression before therapy between active CDc and active CDi, 
especially for the growth factors. Before infliximab therapy, our microarray study 
further showed that the gene expression of 8 MMPs (MMP1, 2, 3, 7, 9, 10, 12 & 19), 
3 TIMPs (TIMP1, 2 & 3), 5 ADAM(TS)s (ADAM9, 19 & 28 and ADAMTS1 & 9) and 
many growth factors was significantly upregulated, whereas only the expression of 
MMP28 and TGFA was significantly downregulated before therapy in inflamed colon 
in UC and/or CDc as compared to control colons. As earlier described (26), the most 
upregulated gene in IBDc inflamed colon is the cell proliferation gene REG1A (>50-
fold). Besides IBD, upregulated REG1A is also associated with type 1 diabetes, 
celiac disease and pancreatic cancer (27-29), and has been proposed to act as a 
mitogenic and/or an anti-apoptotic factor in the development of UC-associated 
neoplasia (30). Moreover, the analysis of protein levels and localization with 
immunohistochemistry demonstrated that REG1A was expressed by Paneth cells in 
normal conditions, whereas in active disease REG1A levels increased and the 
expression shifted towards all epithelial cells of the mucosal crypts. These data 
confirm previous studies, whereby REG1A gene and protein expression levels were 
studied in inflamed and control colonic mucosa(31;32).  
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The strong significantly upregulated (> 10-fold) MMP1, 3, 7, 10 & 12 in active IBD 
colon were previously listed as one of the top upregulated genes in IBD colon in a 
large scale microarray study using open-access IBD datasets (26). In CDi before 
therapy, the expression levels of 4 MMPs (MMP1, 3, 7 & 10), TIMP1 and TFF1 were 
significantly increased, and ADAMDEC1 and AGT were significantly decreased vs. 
control ileums. Of notice, AGT expression levels were decreased in active CDi ileum 
and no correlation was seen with the epithelial marker VIL1, whereas it was 
increased in active IBDc colon and a positive correlation was found with the 
inflammatory marker IL8, suggesting that AGT may play a causative role in CDi 
ileum. In earlier studies it was shown that the renin-angiotensin system is involved in 
colonic inflammation and fibrosis associated with IBD (33), but not much is known 
about its involvement in ileal IBD. The dysregulated expression of nearly all 
mediators present at baseline normalized after infliximab therapy in responders, but 
not in non-responders. The expression of almost all upregulated genes at baseline in 
active disease correlated strongly with the granulocyte markers S100A8, S100A9 and 
S100A12, and the inflammatory marker IL8, whereas the expression of the 
downregulated genes at baseline in active IBD correlated well with the epithelial 
marker VIL1. Both findings suggest that these dysregulations in active IBD are a 
consequence of the severe inflammation and epithelial damage in the intestine. Only 
the expression of 3 growth factors (AREG, JAG1 in colon and AGT in ileum) 
remained significantly dysregulated after infliximab therapy in responders vs. 
controls. Further, the balance between MMPs and TIMPs is crucial, since any 
imbalance can result in an abnormally increased ECM turnover and remodeling, 
which can promote disease progression. In our study, MMP1, 3, 10 & 12 expression 
levels were increased to a much greater extent (17-86x) than those of TIMPs (2-12x) 
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in active IBDc before therapy vs. control colons. This is suggestive for an increased 
net MMP activity in IBDc which might partly explain the tissue destruction in IBD. This 
is in accordance with previously published data (34). The imbalance of MMP/TIMP 
was restored in IBDc responders to infliximab who developed complete mucosal 
healing. The increased ratios of MMP1, 3 and 10 vs.TIMP1 was also seen before 
therapy in CDi inflamed ileum. Previous studies showed that infliximab treatment of 
IBD intestinal mucosal implants decreased the ratio between MMP1, 3 & 9 and both 
TIMP1 & 2 (35). A gelatin degradation assay was performed to determine the net 
gelatinolytic activity in a subset of IBDc (n=3), CDi (n=3) and control individuals 
(n=6). These data suggested that higher net gelatinolytic activity was present in 
mucosal biopsies before infliximab and the activity decreased to control levels after 
infliximab. Zymography analysis performed in this study showed that gelatinase 
(MMP2 and MMP9) levels had a trend to decrease after infliximab. These data were 
expected, since previous studies have shown that MMP2 and MMP9 decreased in 
mucosal biopsies (36) and serum (37) following infliximab therapy in CD. 
Interestingly, 1 CDi and 1 IBDc responder patient had particularly high net 
gelatinolytic activity levels and these patients also had the highest gelatinase levels 
as measured by zymography analysis (CDiR1 w0 and UCR1 w0, see 
supplementary figure 1). In addition, these high mucosal gelatinolytric activities 
normalized to control levels after treatment of with infliximab. This highlights the 
advantage of using both zymography analysis and a gelatin degradation assay. The 
combination of the tests enables to give information on presence, in a semi-
quantitative manner, and activity of the gelatinases in a biological sample (21)). 
Immunohistochemistry analysis of the highest upregulated genes (MMP1, MMP3, 
TIMP1 and REG1A) confirmed the microarray data and showed higher protein 
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expression levels in active disease. These data are in line with previous studies 
(32;34;38). 
Various conclusions emerge from our analyses: (i) in comparison with 
developmentally regulated ADAM(TS)s, inflammation-associated MMPs are stronger 
induced in IBD tissue vs. controls; (ii) TIMP1 (major inhibitor of MMP9) is co-induced 
at similar levels in IBDc as its major proteinase; (iii) many growth factors are switched 
on in active IBD tissue biopsies, suggesting regenerative processes; (iv) infliximab 
restores many of the dysfunctional expressions which underlines the role of TNF as 
an important switch for MMP and growth factor expression; and (v) the excellent 
correlation between clinical (endoscopic and histologic) differences of responders 
and non-responders and alterations in gene expression profiling suggests that both 
cellular and molecular signatures can be practically used in future studies. 
Furthermore, our group showed in a previous microarray study that prior to infliximab 
therapy the gene expression levels of MMP1, 2, 3, 9, 10, 13 & 19 were lower in UC 
and/or CDc responders when compared to UC/CDc non-responders to infliximab 
(15;39), suggesting that these MMP genes are predictive for non-response of 
infliximab in IBDc.  
Our data suggest that the critical step in mucosal healing in IBD is control of 
inflammation, blockade of migration of leukocytes and elimination of the inflammatory 
cells from the tissue. Consequently, the MMPs and TIMPs decrease or normalize and 
the imbalance of MMP/TIMP is restored in IBD responders to infliximab. Growth 
factors are upregulated with active inflammation. With mucosal healing, we observe a 
decrease of most growth factor expression to normal levels, suggesting that there is 
no need for an excess of these mediators to maintain healing. Our studies, therefore, 
indicate that the biological targets in IBD are mainly the key inflammatory mediators 
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and the inflammatory cells. Targeting MMPs, TIMPS, ADAM(TS)s and growth factors 
may be beneficial in specific patients not responding to anti-TNF therapy but it is 
unlikely to achieve the same dramatic effects as the approach of targeting upstream 
inflammatory molecules or cells.  
 
FIGURE LEGENDS 
Figure 1: qRT-PCR analysis of MMP1 (A), MMP28 (B), TIMP1 (C), ADAM9 (D), 
TFF1 (E) and TGFB1 (F) in intestinal mucosa from IBD patients before and after first 
infliximab treatment and controls. A line between 2 points represents the change in 
expression before and after treatment for one patient. The x-axis labels of subfigures 
1A, 1B, 1C and 1D are similar as shown in subfigure 1E and 1F. CDi: Crohn’s ileitis, 
IBDc: colonic inflammatory bowel disease, NR: infliximab non-responders, R: 
infliximab responders, *significant p-value ≤ 0.01.  
 
Figure 2: The ratio MMP1/TIMP1 in intestinal mucosa from IBD patients before and 
after first infliximab treatment and controls, using the qRT-PCR expression data of 
MMP1 and TIMP1. A line between 2 points represents the change in expression 
before and after treatment for one patient. CDi: Crohn’s ileitis, IBDc: colonic 
inflammatory bowel disease, NR: infliximab non-responders, R: infliximab 
responders, *significant p-value ≤ 0.01.  
 
Figure 3: Mucosal tissues from active CDi patients, IBDc patients and controls were 
stained by immunohistochemistry to localize MMP1 (A), MMP3 (B), REG1A (C) and 
TIMP1 (D). Arrow heads in the lower panel D indicate TIMP1 expression in 
Page 26 of 42Inflammatory Bowel Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
26 
 
enteroendocrine cells. Images were taken at 4X and 20X magnification, scale bars 
are shown in the right lower corner.  
 
Figure 4: Gelatin zymography analysis on mucosal biopsies from active CDi and 
IBDc responders before and after treatment with infliximab, and controls. Levels of 
MMP9 and MMP2 forms are represented as a ratio vs. proMMP2 levels. Mean values 
with standard deviation of the mean (SEM) are shown. IBDcR: IBD colitis responder 
to infliximab, CDiR: CD ileitis responder to infliximab. 
 
Figure 5: Gelatin degradation assay on mucosal biopsies from active CDi and IBDc 
responders before and after treatment with infliximab, and controls. Gelatinolytic 
activity is represented by fluorescence units over time. Mean values with standard 
deviation of the mean (SEM) are shown. IBDcR: IBD colitis responder to infliximab, 
CDiR: CD ileitis responder to infliximab. 
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Table 1: Characteristics of IBD patients at first infliximab infusion and of control individuals. 
Baseline characteristics 
IBD (n:61) Controls (n:12) 
P-valueIBD vs. controls 
UC (n:24) CDc (n:19) CDi (n:18) Controls colon (n:6) Controls ileum (n:6) 
Male/Female (%) 14/10 (58.3/41.7) 11/8 (57.9/42.1) 9/9 (50/50) 3/3 (50/50) 3/3 (50/50) 0.759 
Median (IQR)* age (years) 41.4 (31.9-50.9) 31.8 (23.7-47.5) 46.4 (34-55.3) 73.07 (71.31-76.67) 51.8 (34.11-57.33) 0.002 
Median (IQR)* duration of disease prior to first IFX 
(years) 7.3 (2.7-17.1) 6.4 (3.1-20.9) 22.3 (11.1-28) NA NA NA 
Extent of disease             
     UC Left-sided colitis (%) 7 (29.2) NA NA NA NA NA 
           Pancolitis (%) 17 (70.8) NA NA NA NA NA 
     CD Ileocolon (%) NA 5 (26.3) 9 (50) NA NA NA 
           Ileum (%) NA 0 (0) 9 (50) NA NA NA 
           Colon (%) NA 14 (73.7) 0 (0) NA NA NA 
Median (IQR)* C-reactive protein at first IFX (mg/L) 4 (1.8-19.1) 10.2 (4.3-35) 7.4 (2.3-10.9) NA NA NA 
Concomitant medication at first IFX (%)             
     5-Aminosalicylates 18 (75) 8 (42.1) 5 (27.8) NA NA NA 
     Corticosteroids 7 (29.2) 4 (21.1) 2 (11.1) NA NA NA 
     Azathioprine/6-Mercaptopurine 15 (62.5) 14 (73.7) 7 (38.9) NA NA NA 
     Methotrexate 0 (0) 0 (0) 0 (0) NA NA NA 
     Corticosteroids + Immunosuppressants 3 (12.5) 2 (10.5) 1 (6) NA NA NA 
Active smoking (%) 2 (8.3) 6 (31.6) 6 (33.3) 0 (0) 1 (16.7) 0.438 
*: datasets with skewed (non-normal) distributions, IQR: interquartile range, IFX: infliximab, NA: not applicable       
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Table 2: Fold changes of the probe sets encoding MMP, TIMP and ADAM(TS) genes that were 
significantly different in the comparative analyses before therapy in IBDc inflamed colon versus 
control colons, and fold changes of these probe sets from the comparative analyses after 
infliximab therapy in IBDc. The abbreviations of the individual MMPs, TIMPs and ADAM(TS)s are 
explained in supplementary table 1.  
Probe Set ID Gene Symbol 
IBDc before IFX 
(n=43) 
IBDc R after IFX 
(n=19) 
IBDc NR after IFX 
(n=23) 
IBDc R after IFX 
(n=19) 
IBDc NR after IFX 
(n=23) 
vs. vs. vs. vs. vs. 
control colons 
(n=6) 
control colons 
(n=6) 
control colons 
(n=6) 
IBDc R before IFX 
(n=19) 
IBDc NR before 
IFX (n=23) 
204475_at MMP1 85.57* 1.76 54.66* 0.05* 0.33 
201069_at MMP2 4.09* 1.11 4.18* 0.52* 0.62 
205828_at MMP3 67.93* 1.27 42.97* 0.04* 0.32 
204259_at MMP7 8.00* 1.53 5.36* 0.25* 0.55 
203936_s_at MMP9 7.81* 1.34 4.56* 0.27* 0.40 
205680_at MMP10 16.98* 1.40 11.50* 0.19* 0.34 
204580_at MMP12 28.72* 2.24 21.54* 0.11* 0.54 
204575_s_at MMP19 2.08* 1.09 2.42* 0.81* 0.81 
219909_at MMP28 0.33* 0.79 0.38* 2.20* 1.21 
239273_s_at MMP28 0.42* 0.70 0.41* 1.61* 1.01 
201666_at TIMP1 11.51* 2.90 9.95* 0.39* 0.61 
224560_at TIMP2 2.16* 1.03 2.00 0.68* 0.71 
1555326_a_at ADAM9 2.10* 1.02 1.82 0.51* 0.80 
202381_at ADAM9 2.01* 1.33 1.91* 0.69* 0.91 
209765_at ADAM19 2.62* 1.21 2.48* 0.61* 0.75 
205997_at ADAM28 3.54* 1.25 2.84* 0.50* 0.61 
222162_s_at ADAMTS1 3.96* 2.65 6.04* 1.12 0.97 
226814_at ADAMTS9 3.17* 1.46 3.36* 0.60* 0.83 
*: FDR < 0.05, underline: significant (> 2-fold change and FDR < 0.05), IFX: infliximab, R: responders, NR: non-responders 
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Table 3: Fold changes of the probe sets encoding MMP, TIMP and ADAM(TS) genes that were 
significantly different in the comparative analyses before therapy in CDi inflamed ileum versus 
control ileums, and fold changes of these probe sets from the comparative analyses after 
infliximab therapy. The abbreviations of the individual MMPs, TIMPs and ADAM(TS)s are 
explained in supplementary table 1. 
Probe Set ID 
Gene 
Symbol 
CDi before IFX (n:18) CDi R after IFX (n:8) 
CDi NR after IFX 
(n:10) 
CDi R after IFX (n:8) 
CDi NR after IFX 
(n:10) 
vs. vs. vs. vs. vs. 
control ileums (n:6) control ileums (n:6) control ileums (n:6) 
CDi R before IFX 
(n:8) 
CDi NR before IFX 
(n:10) 
204475_at MMP1 22.04* 7.21 21.12* 0.63 0.57 
205828_at MMP3 47.58* 2.82 24.92* 0.15 0.25 
204259_at MMP7 3.27* 2.01 2.40 0.86 0.56 
205680_at MMP10 6.69* 1.82 3.74 0.40 0.41 
201666_at TIMP1 5.71* 1.79 5.57* 0.48 0.70 
206134_at ADAMDEC1 0.42* 0.35 0.32 0.79 0.80 
*: FDR < 0.05, underline: significant (> 2-fold change and FDR < 0.05), IFX: infliximab, R: responders, NR: non-responders 
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Table 4: Fold changes of the probe sets encoding growth factor genes that were significant at 
baseline between active CDi and active CDc. The abbreviations of the individual growth factors 
are explained in supplementary table 1. 
Probe Set ID Gene Symbol 
CDi before IFX (n:18) 
vs. 
CDc before IFX 
(n:19) 
205239_at AREG 0.23* 
205289_at BMP2 0.42* 
205290_s_at BMP2 0.42* 
209101_at CTGF 0.42* 
206404_at FGF9 2.57* 
206268_at LEFTY1 0.06* 
1559361_at MACC1 2.17* 
1566764_at MACC1 3.31* 
1566766_a_at MACC1 2.30* 
232151_at MACC1 2.50* 
205614_x_at MST1 2.41* 
216320_x_at MST1 2.69* 
218718_at PDGFC 2.03* 
*: FDR < 0.05, underline: significant (> 2-fold change 
and FDR < 0.05), IFX: infliximab 
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Table 5: The fold changes of the probe sets encoding growth factor genes that were significantly 
different in the comparative analyses before therapy in IBDc inflamed colon versus control colons, 
and the fold changes of these probe sets from the comparative analyses after infliximab therapy in 
IBDc. The abbreviations of the individual growth factors are explained in supplementary table 1. 
Probe Set ID Gene Symbol 
IBDc before 
IFX (n=43) 
IBDc R after 
IFX (n=19) 
IBDc NR after 
IFX (n=23) 
IBDc R after 
IFX (n=19) 
IBDc NR after 
IFX (n=23) 
vs. vs. vs. vs. vs. 
control colons 
(n=6) 
control colons 
(n=6) 
control colons 
(n=6) 
IBDc R before 
IFX (n=19) 
IBDc NR before 
IFX (n=23) 
202834_at AGT 2.67* 1.13 2.24* 0.55* 0.69 
213001_at ANGPTL2 2.90* 1.12 2.91* 0.66* 0.65 
205239_at AREG 3.52* 3.84* 4.67* 1.08 1.28 
219505_at CECR1 3.37* 1.33 3.11* 0.56* 0.69 
209101_at CTGF 2.70* 1.77 3.24* 0.87 0.93 
1554741_s_at 
FGF7/  
KGFLP1/  
KGFLP2 
3.94* 1.60 4.78* 0.78 0.71 
204220_at GMFG 3.35* 1.14 3.57* 0.48* 0.79 
203821_at HBEGF 2.34* 3.00 3.56* 1.28 1.43 
209524_at HDGFRP3 2.15* 1.44 2.45* 0.98 0.82 
210511_s_at INHBA 3.19* 0.77 3.62 0.51* 0.59 
231183_s_at JAG1 2.71* 2.30* 2.61* 0.87 0.96 
202655_at MANF 2.33* 1.49 2.38* 0.67* 0.97 
209752_at REG1A 71.30* 3.36 31.27* 0.05* 0.42 
205009_at TFF1 2.94* 1.60 2.52* 0.61* 0.76 
214476_at TFF2 2.62* 1.30 1.96 0.58* 0.64 
205016_at TGFA 0.45* 0.57 0.42* 1.31 0.91 
203085_s_at TGFB1 2.42* 1.10 2.48* 0.72* 0.72 
204858_s_at TYMP 2.35* 1.12 2.16* 0.56* 0.79 
*: FDR < 0.05, underline: significant (> 2-fold change and FDR < 0.05), IFX: infliximab, R: responders, NR: non-responders 
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Table 6: The fold changes of the probe sets encoding growth factor genes that were significantly 
different in the comparative analyses before therapy in CDi inflamed ileum versus control ileums, 
and the fold changes of these probe sets from the comparative analyses after infliximab therapy. 
The abbreviations of the individual growth factors are explained in supplementary table 1. 
Probe Set ID 
Gene 
Symbol 
CDi before IFX 
(n:18) 
CDi R after IFX (n:8) 
CDi NR after IFX 
(n:10) 
CDi R after IFX (n:8) 
CDi NR after IFX 
(n:10) 
vs. vs. vs. vs. vs. 
control ileums (n:6) control ileums (n:6) control ileums (n:6) 
CDi R before IFX 
(n:8) 
CDi NR before IFX 
(n:10) 
202834_at AGT 0.33* 0.28* 0.28* 0.92 0.80 
205009_at TFF1 2.94* 2.03 3.17* 0.95 0.83 
*: FDR < 0.05, underline: significant (> 2-fold change and FDR < 0.05), IFX: infliximab, R: responders, NR: non-responders 
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